



## Special Executive Report

---

S-7939

June 7, 2017

### **Reminder Regarding the Prohibited Use of Test Orders During the Pre-Open Period on Globex**

Market participants are reminded that the CME Group Market Regulation Advisory Notice on Rule 575 (“Disruptive Practices Prohibited”) prohibits entering an order(s) in a non-test product without the intent to execute a bona fide transaction, including for the purpose of verifying connectivity or checking a data feed. This prohibition applies to all market states on CME Globex, including the pre-open period, and is covered in the Disruptive Practices Prohibited Market Regulation Advisory Notice located on the Current Market Regulation Advisory Notice [webpage](#).

Additionally, please note that CME Group offers test products in the production environment to facilitate connectivity and messaging testing on CME Globex. Information about CME Group test products can be found here:

<http://www.cmegroup.com/confluence/display/EPICSANDBOX/CME+Globex+Test+Products>.

Questions concerning this Special Executive Report may be directed to the following individuals in the Market Regulation Department:

Natasha Selkov, Lead Investigator, 312.341.7623

Colin Garvey, Manager, Investigations, 312.435.3656

For media inquiries concerning this Special Executive Report, please contact CME Group Corporate Communications at 312.930.3434.